JP2004509854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509854A5 JP2004509854A5 JP2002513407A JP2002513407A JP2004509854A5 JP 2004509854 A5 JP2004509854 A5 JP 2004509854A5 JP 2002513407 A JP2002513407 A JP 2002513407A JP 2002513407 A JP2002513407 A JP 2002513407A JP 2004509854 A5 JP2004509854 A5 JP 2004509854A5
- Authority
- JP
- Japan
- Prior art keywords
- glycero
- pharmaceutical composition
- phosphocholine
- valproic acid
- valproyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 33
- 239000008194 pharmaceutical composition Substances 0.000 description 19
- 150000003904 phospholipids Chemical class 0.000 description 18
- 229960000604 valproic acid Drugs 0.000 description 16
- RVDTYQONAYYEBB-SSEXGKCCSA-N [(2r)-3-hexadecanoyloxy-2-(2-propylpentanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)C(CCC)CCC)COP([O-])(=O)OCC[N+](C)(C)C RVDTYQONAYYEBB-SSEXGKCCSA-N 0.000 description 6
- 229950004354 phosphorylcholine Drugs 0.000 description 5
- UHNWBZZXSLGXSM-JGCGQSQUSA-N [(2r)-3-octadecanoyloxy-2-(2-propylpentanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)C(CCC)CCC)COP([O-])(=O)OCC[N+](C)(C)C UHNWBZZXSLGXSM-JGCGQSQUSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- -1 1-hexadecanoyl Chemical group 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/614,271 US6313106B1 (en) | 1995-06-07 | 2000-07-12 | Phospholipid derivatives of valproic acid and mixtures thereof |
| US09/614,271 | 2000-07-12 | ||
| PCT/IL2001/000629 WO2002007669A2 (en) | 2000-07-12 | 2001-07-10 | Phospholipid derivatives of valproic acid and mixtures thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004509854A JP2004509854A (ja) | 2004-04-02 |
| JP2004509854A5 true JP2004509854A5 (https=) | 2008-07-17 |
| JP5140224B2 JP5140224B2 (ja) | 2013-02-06 |
Family
ID=24460534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002513407A Expired - Fee Related JP5140224B2 (ja) | 2000-07-12 | 2001-07-10 | バルプロ酸のリン脂質誘導体およびそれらの混合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6313106B1 (https=) |
| EP (1) | EP1315506B1 (https=) |
| JP (1) | JP5140224B2 (https=) |
| KR (1) | KR100801213B1 (https=) |
| CN (1) | CN100536851C (https=) |
| AT (1) | ATE461697T1 (https=) |
| AU (2) | AU7096201A (https=) |
| BR (1) | BR0112337A (https=) |
| CA (1) | CA2415354C (https=) |
| CY (1) | CY1110113T1 (https=) |
| CZ (1) | CZ305745B6 (https=) |
| DE (1) | DE60141636D1 (https=) |
| DK (1) | DK1315506T3 (https=) |
| ES (1) | ES2343403T3 (https=) |
| HU (1) | HU229320B1 (https=) |
| IL (1) | IL153147A0 (https=) |
| MX (1) | MXPA03000326A (https=) |
| NZ (1) | NZ522788A (https=) |
| PT (1) | PT1315506E (https=) |
| WO (1) | WO2002007669A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313106B1 (en) * | 1995-06-07 | 2001-11-06 | D-Pharm Ltd. | Phospholipid derivatives of valproic acid and mixtures thereof |
| US6518311B2 (en) * | 1997-07-09 | 2003-02-11 | D-Pharm Ltd. | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain |
| US7582678B2 (en) | 1997-07-09 | 2009-09-01 | D-Pharm Limited | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain |
| CN1649600A (zh) | 2002-02-28 | 2005-08-03 | A&D生物科学公司 | 氟西汀及类似物的糖醛酰胺、苷和原酸酯苷及其应用 |
| WO2003079980A2 (en) * | 2002-03-19 | 2003-10-02 | A & D Bioscience, Inc. | Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof |
| WO2003086475A1 (en) * | 2002-04-12 | 2003-10-23 | A & D Bioscience, Inc. | Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof |
| CA2484891A1 (en) * | 2002-05-07 | 2003-11-20 | A & D Bioscience, Inc. | Conjugates comprising central nervous system active drug |
| US20050215487A1 (en) * | 2002-06-27 | 2005-09-29 | Holick Michael F | Conjugates comprising an nsaid and a sugar and uses thereof |
| US20050170063A1 (en) * | 2004-01-29 | 2005-08-04 | Lalit Chordia | Production of powder and viscous material |
| GB2460976B (en) * | 2005-03-24 | 2010-02-17 | John Marcell Davis | Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders |
| WO2007028030A2 (en) * | 2005-09-02 | 2007-03-08 | Picobella, Llc | Oncogenic regulatory rnas for diagnostics and therapeutics |
| US7459280B2 (en) * | 2006-02-27 | 2008-12-02 | Picobella, Llc | Methods for diagnosing and treating kidney cancer |
| US20080267977A1 (en) * | 2007-04-26 | 2008-10-30 | Friedrich-Alexander University Of Erlangen-Nuremberg | Combined immunological agent and sensitizing agent for the treatment of cancer |
| KR200451744Y1 (ko) * | 2008-10-10 | 2011-01-10 | 이종희 | 휴대용 운동기구 |
| JP2015533114A (ja) * | 2012-05-08 | 2015-11-19 | セリックスビオ プライヴェート リミテッド | 神経疾患の治療のための組成物及び方法 |
| CN104230981B (zh) * | 2013-06-20 | 2016-05-18 | 江苏恩华药业股份有限公司 | 丙戊酸磷脂衍生物的制备方法 |
| PT3429580T (pt) * | 2016-03-16 | 2025-08-12 | Buzzelet Development And Technologies Ltd | Composição de canabinoides enriquecida em terpenos |
| CN108659038B (zh) * | 2017-03-31 | 2022-01-11 | 江苏恩华药业股份有限公司 | 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法 |
| CN108659037B (zh) * | 2017-03-31 | 2022-01-11 | 江苏恩华药业股份有限公司 | 丙戊酸磷脂衍生物的多晶型物及制备方法 |
| KR101864085B1 (ko) * | 2017-09-22 | 2018-06-01 | 동아대학교 산학협력단 | 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제 |
| CN110407867A (zh) * | 2018-04-28 | 2019-11-05 | 江苏恩华药业股份有限公司 | 丙戊酸磷脂衍生物的新晶型及其制备方法 |
| CN114344303B (zh) * | 2022-01-13 | 2023-05-09 | 江苏海洋大学 | 一种新型精神药物固体分散体及制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4654370A (en) * | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
| US4988731A (en) | 1979-08-20 | 1991-01-29 | Abbott Laboratories | Sodium hydrogen divalproate oligomer |
| US5212326A (en) | 1979-08-20 | 1993-05-18 | Abbott Laboratories | Sodium hydrogen divalproate oligomer |
| US4558070A (en) | 1983-10-26 | 1985-12-10 | Abbott Laboratories | Acid salts of valproic acid |
| CA1260393A (en) * | 1984-10-16 | 1989-09-26 | Lajos Tarcsay | Liposomes of synthetic lipids |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| IT1201149B (it) | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche |
| ATE151467T1 (de) | 1987-11-30 | 1997-04-15 | Univ Iowa Res Found | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene |
| DE3801587A1 (de) | 1988-01-21 | 1989-08-03 | Hoechst Ag | Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung |
| CA2049028A1 (en) | 1989-03-07 | 1990-09-08 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| JPH03133987A (ja) | 1989-10-18 | 1991-06-07 | Kowa Yakuhin Kogyo Kk | ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法 |
| WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| CH679856A5 (https=) | 1990-07-04 | 1992-04-30 | Lonza Ag | |
| US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
| AU668873B2 (en) | 1991-07-12 | 1996-05-23 | Chimerix, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
| US6015834A (en) | 1992-10-20 | 2000-01-18 | Toronto Neuroprotection Group | In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer |
| IL105244A (en) | 1993-03-31 | 2003-07-31 | Dpharm Ltd | Prodrugs with enhanced penetration into cells |
| US6413949B1 (en) | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
| US6313106B1 (en) * | 1995-06-07 | 2001-11-06 | D-Pharm Ltd. | Phospholipid derivatives of valproic acid and mixtures thereof |
| IL121268A0 (en) * | 1997-07-09 | 1998-01-04 | Dpharm Ltd | Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders |
| KR100301803B1 (ko) | 1998-06-05 | 2001-09-22 | 김영환 | 박막트랜지스터 및 그의 제조방법 |
-
2000
- 2000-07-12 US US09/614,271 patent/US6313106B1/en not_active Expired - Lifetime
-
2001
- 2001-07-10 HU HU0302635A patent/HU229320B1/hu not_active IP Right Cessation
- 2001-07-10 PT PT01949851T patent/PT1315506E/pt unknown
- 2001-07-10 CN CNB018151736A patent/CN100536851C/zh not_active Expired - Lifetime
- 2001-07-10 CZ CZ2003-86A patent/CZ305745B6/cs not_active IP Right Cessation
- 2001-07-10 CA CA002415354A patent/CA2415354C/en not_active Expired - Fee Related
- 2001-07-10 AT AT01949851T patent/ATE461697T1/de active
- 2001-07-10 NZ NZ522788A patent/NZ522788A/en not_active IP Right Cessation
- 2001-07-10 AU AU7096201A patent/AU7096201A/xx active Pending
- 2001-07-10 DE DE60141636T patent/DE60141636D1/de not_active Expired - Lifetime
- 2001-07-10 BR BR0112337-8A patent/BR0112337A/pt not_active Application Discontinuation
- 2001-07-10 DK DK01949851.8T patent/DK1315506T3/da active
- 2001-07-10 EP EP01949851A patent/EP1315506B1/en not_active Expired - Lifetime
- 2001-07-10 MX MXPA03000326A patent/MXPA03000326A/es active IP Right Grant
- 2001-07-10 AU AU2001270962A patent/AU2001270962B8/en not_active Ceased
- 2001-07-10 WO PCT/IL2001/000629 patent/WO2002007669A2/en not_active Ceased
- 2001-07-10 JP JP2002513407A patent/JP5140224B2/ja not_active Expired - Fee Related
- 2001-07-10 ES ES01949851T patent/ES2343403T3/es not_active Expired - Lifetime
- 2001-07-10 KR KR1020027017319A patent/KR100801213B1/ko not_active Expired - Fee Related
- 2001-07-10 US US10/312,895 patent/US20040033987A1/en not_active Abandoned
- 2001-07-10 IL IL15314701A patent/IL153147A0/xx unknown
-
2010
- 2010-05-28 CY CY20101100472T patent/CY1110113T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004509854A5 (https=) | ||
| DE69924258T2 (de) | Durch einen omega-thiarest substituierte phenyl-prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten | |
| DE69232101T2 (de) | Lipid-derivate von phosphonsäuren für liposomale inkorporation und verwendungsverfahren | |
| JPH07500573A (ja) | 抗ウィルス性リポヌクレオシド：ｂ型肝炎の治療 | |
| DE69819016T2 (de) | Arginine silicate inositol komplex und dessen verwendung | |
| CA1336498C (en) | Pharmaceutical formulations for parenteral use | |
| JPS62155288A (ja) | 高純度アカルボ−ス | |
| JP2002511406A (ja) | 感染症の治療および予防処置のための有機リン化合物の使用 | |
| CN102884041A (zh) | 阳离子性脂质 | |
| DE60017801T2 (de) | Inhalierung von anti-endotoxinmitteln zur vorbeugung oder behandlung von bakterieller lungeninfektion oder symptomatischer endotoxinaussetzung der lunge | |
| JP2017517550A (ja) | トレプロスチニル製剤 | |
| JPH05163139A (ja) | 抗動脈硬化剤 | |
| TW593331B (en) | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof | |
| JP4284564B2 (ja) | イノシトール燐酸のバイオアベイラビリティを向上させた薬剤組成物 | |
| JPS61501391A (ja) | デフェロキサミンに関連する経口的に有効なイオンキレ−ト化剤 | |
| JPH11508905A (ja) | アミノ置換ビスホスホン酸 | |
| DE19920247A1 (de) | Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung | |
| JPS59501211A (ja) | 燐脂質合成用の新規グリセリン誘導体 | |
| EP2170920A1 (en) | Stable salts of s-adenosylmethionine and process for the preparation thereof | |
| JPH10500977A (ja) | ピリジルビスホスホン酸エステルよりなる治療用活性薬剤 | |
| JP2003520760A (ja) | 感染症の治療および予防処置用医薬製剤の製造のための、または植物における殺真菌剤、殺菌剤もしくは除草剤としての使用 | |
| ATE165822T1 (de) | Chinolin-4-carbonylguanidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| DE19854403A1 (de) | Phosphororganische Verbindungen und ihre Verwendung | |
| JP2004528364A5 (https=) | ||
| DE69023459T2 (de) | Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten. |